NovaBridge Biosciences Business Summary

NovaBridge Biosciences (NBP) operates as a global biotechnology "hub-and-spoke" platform, generating revenue through a business development-led model focused on asset monetization via licensing agreements, strategic acquisitions, and therapeutic spin-outs. The company specializes in two primary business segments: precision immuno-oncology and ophthalmology, where it identifies and accelerates Asian-origin biologic assets through midstream clinical proof-of-concept and de-risking. Its differentiated pipeline is headlined by givastomig (a CLDN18.2 x 4-1BB bispecific antibody) and VIS-101 (a VEGF-A/ANG2 bifunctional biologic). Within the competitive landscape, NBP contends with clinical-stage peers such as Eupraxia Pharmaceuticals, Ocugen, Inc., and Assembly Biosciences, positioning itself as a specialized strategic bridge that internationalizes high-potential innovation for global markets. The leadership team is anchored by Executive Chairman Wei Fu, who also serves as the CEO of CBC Group, the company’s primary institutional investor. The executive suite is led by CEO Sean (Xi-Yong) Fu, PhD, MBA, an experienced industry veteran who previously held leadership roles at I-Mab and Luye Pharma. Key management includes Chief Financial Officer Kyler Lei, Chief Business Development Officer Sean Cao, PhD, and Chief Medical Officer Phillip Dennis, MD, PhD, who brings extensive oncology expertise from AstraZeneca and Johns Hopkins. The board of directors features notable industry figures such as Ian Woo and Dr. Robert Lenz, supported by a Scientific Advisory Board of world-class oncologists and ophthalmologists. This leadership pedigree, combined with the strategic backing of CBC Group, provides NBP with the capital and cross-border expertise necessary to execute its high-velocity clinical development strategy.